59 results on '"Lanctôt, Krista L."'
Search Results
2. A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease
3. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
4. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
5. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005–2017)
6. Association between endothelial function and cognitive performance in patients with coronary artery disease during cardiac rehabilitation
7. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab
8. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab
9. Lithium Carbonate in a Poststroke Population: Exploratory Analyses of Neuroanatomical and Cognitive Outcomes
10. Lithium Carbonate in a Poststroke Population: Exploratory Analyses of Neuroanatomical and Cognitive Outcomes
11. Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia
12. The effect of white matter hyperintensities on verbal memory: Mediation by temporal lobe atrophy
13. Cognitive Outcomes After Transcatheter Aortic Valve Implantation: A Metaanalysis
14. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies
15. “Good Outcome” Isn’t Good Enough: Cognitive Impairment, Depressive Symptoms, and Social Restrictions in Physically Recovered Stroke Patients
16. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study
17. Validating a Pragmatic Approach to Cognitive Screening in Stroke Prevention Clinics Using the Montreal Cognitive Assessment
18. Bias in Peripheral Depression Biomarkers
19. Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015
20. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimerʼs Disease
21. Platelet activating factors in depression and coronary artery disease: A potential biomarker related to inflammatory mechanisms and neurodegeneration
22. Potential roles of zinc in the pathophysiology and treatment of major depressive disorder
23. Interleukin-17 in post-stroke neurodegeneration
24. A review of cost–effectiveness of palivizumab for respiratory syncytial virus
25. Serotonergic Function and Treatment of Behavioral and Psychological Symptoms of Frontotemporal Dementia
26. Current and Emerging Drug Treatment Options for Alzheimerʼs Disease: A Systematic Review
27. The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimerʼs Disease
28. Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimerʼs Disease: An Open-Label Pilot Study
29. Pediatric Cancer Rates After Universal Folic Acid Flour Fortification In Ontario
30. The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
31. Cardiopulmonary Fitness Is Associated with Cognitive Performance in Patients with Coronary Artery Disease
32. Factor Analysis of the Rivermead Post-Concussion Symptoms Questionnaire in Mild-to-Moderate Traumatic Brain Injury Patients
33. A brief history of poststroke depression neuroimaging
34. Commentary: Aβ(1–42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels
35. Apathy Associated with Alzheimer Disease: Use of Dextroamphetamine Challenge
36. A Positron Emission Tomography Study of 5-Hydroxytryptamine-1A Receptors in Alzheimer Disease
37. Cholinesterase Inhibitors Slow Decline in Executive Functions, Rather than Memory, in Alzheimerʼs Disease: A 1-Year Observational Study in the Sunnybrook Dementia Cohort
38. Atypical Antipsychotics for Neuropsychiatric Symptoms of Dementia: Malignant or Maligned?
39. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
40. ERECTILE DYSFUNCTION IN SPINAL CORD INJURY: A COST-UTILITY ANALYSIS
41. Psychotropic Medication and Stroke Outcome
42. Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease
43. Do Atypical Antipsychotics Cause Stroke?
44. Medial Temporal Hypoperfusion and Aggression in Alzheimer Disease
45. Atypical Antipsychotics and Risk of Cerebrovascular Accidents
46. Drug therapy for Alzheimerʼs disease
47. Efficacy and safety of cholinesterase inhibitors in Alzheimerʼs disease: a meta-analysis
48. The Cost-Benefit of Cholinesterase Inhibitors in Mild to Moderate Dementia: A Willingness-To-Pay Approach
49. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimerʼs disease
50. Exercise intervention and inflammatory markers in coronary artery disease: A meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.